Sun Life Financial Inc.

Underlying net income was CAD 1.12 billion, up from CAD 1.02 billion last year. Underlying EPS was CAD 2.02, up 13% year over year, and underlying ROE was 19.1%. Reported net income was CAD 1.01 billion versus CAD 716 million a year ago. Canada underlying net income was CAD 427 million, up 23%; U.S. underlying net income increased 15%; Asia underlying net income increased 21%; and Sun Life Asset Management underlying net income was CAD 262 million, up 4%. Insurance sales increased 20%, Asia individual insurance sales were CAD 875 million, and Canada's wealth platform reached CAD 286 billion in AUM/AUA, up 18%. The company ended the quarter with a LICAT ratio of 145%, holding company cash of CAD 2.3 billion, book value per share of CAD 42.49, financial leverage of 23.8%, total CSM of CAD 15.3 billion, and organic capital generation of 41%. Forward-looking commentary pointed to continued broad-based earnings growth, with management reiterating medium-term targets including underlying EPS growth above 10%, ROE approaching 20%, dividend ratio of 40%-50%, and asset management operating margin expected to be over 30% over the coming years.

Kevin Strain framed the quarter as evidence that Sun Life is becoming more diversified, global, and growth-oriented, with strength across Canada, Asia, U.S. health/risk, and asset management. He emphasized that the company is seeing real momentum from strategic priorities like AI, digital transformation, and the unification of Sun Life Asset Management. His tone was confident and constructive, but he also acknowledged that the U.S. dental state business will remain a multi-year challenge as the company shifts toward a more profitable commercial mix.

Tim Deacon said results were driven by stronger contributions from Canada, Asia, the U.S., and asset management, and explained the gap between underlying and reported earnings by acquisition and integration costs in SLC, intangible amortization, and modestly unfavorable net market impacts. He highlighted Canada’s record CAD 427 million underlying net income, U.S. underlying net income up 15%, Asia up 21%, and SLC net income of CAD 262 million, while noting capital raising of CAD 4.7 billion and deployment of CAD 6.2 billion across the platform. On capital, he cited the 145% LICAT ratio, the CAD 750 million sub-debt issuance at the lowest spread for a seven-year issuance in 25 years, and return of roughly half a billion dollars to shareholders through dividends.

Analysts pressed management on U.S. stop-loss margins and why stronger sales were not translating into even more earnings lift; management said Q2 included expected seasonal IBNR reserve buildup, that loss ratios stayed in the mid-70s target range, and that employee benefits was comparing against an unusually strong prior-year quarter. Questions on dental focused on how much government/Medicaid business remains and the timeline for reshaping it; management said the state business will be a smaller part of dental over the next one to two years, with near-term headwinds likely to continue and 2027 market dynamics important. In Asia, analysts asked about Hong Kong’s MCV exposure and new business CSM margin pressure; management said MCV is about 30% of Hong Kong sales, the business is still strong, and current CSM margins are appropriate in the competitive environment. On SLC, management said flows will be lumpy quarter to quarter, but they expect AUM growth, platform efficiencies, and margins to improve over time, with operating margin expected to exceed 30% and potentially reach the mid-30% range over five years.